Aleanna, Inc. current report, 11 August 2023

Full document

Business Context and Reporting Period

Swiftmerge Acquisition Corp., a Cayman Islands blank check company, filed this Form 8-K on August 11, 2023, reporting entry into a definitive merger agreement with HDL Therapeutics, Inc. The filing is also furnished under Regulation FD and relates to a proposed business combination, not a period-end financial report. The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity results for Swiftmerge or HDL.

Transaction Terms and Key Financial Metrics

  • Merger Sub will merge with HDL, with HDL surviving as a wholly owned subsidiary of Swiftmerge.
  • HDL equity holders will receive aggregate consideration consisting of cash and shares of domesticated Swiftmerge common stock valued at $10.00 per share, with a stated total value of $400 million.
  • Eligible HDL stockholders may receive up to 11 million additional earnout shares: 6 million upon achievement of a $12.50 VWAP milestone and 5 million upon achievement of a $15.00 VWAP milestone, each measured over 20 trading days within a 30-trading-day period during the two years following closing.
  • HDL agreed to seek pre-closing financing of up to $2.68 million through December 31, 2023, and up to an additional $3 million thereafter. Certain pre-closing obligations are conditioned on obtaining this financing or having sufficient funds to pay ordinary-course obligations.
  • HDL’s closing condition requires available trust-account cash plus acceptable financing, less specified expenses and payments, to be at least $30 million.
  • After the transaction, Swiftmerge is expected to be renamed HDL Therapeutics, Inc. and to have a five-member board, with one director appointed by the sponsor and four by HDL.
  • Swiftmerge’s public securities are listed on Nasdaq under IVCPU, IVCP, and IVCPW. Each existing warrant will become exercisable for one share of domesticated Swiftmerge common stock, subject to the warrant agreement.

Material Changes Versus the Prior Comparable Period

The filing does not present comparative operating or financial results. The material development is the execution of the merger agreement and related support, registration-rights, and lock-up arrangements.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • Closing remains subject to shareholder approvals, regulatory and governmental approvals, Nasdaq or alternative exchange listing approval, effectiveness of a Form S-4 registration statement, satisfaction of net tangible asset requirements, and other customary conditions.
  • Swiftmerge intends to domesticate from the Cayman Islands into Delaware before closing. Existing ordinary shares, warrants, and units will convert into corresponding Delaware securities.
  • The agreement may be terminated if closing has not occurred by March 15, 2024, subject to a possible extension by Swiftmerge but no later than June 15, 2024, or upon other customary events such as failure to obtain approvals, illegality, uncured breaches, or mutual consent.
  • HDL and certain stockholders waived claims against Swiftmerge’s trust account before closing.
  • The sponsor and certain HDL stockholders agreed to support the transaction and vote in favor of it. Certain securities will be subject to a six-month lock-up, subject to specified release conditions, including a $12.00 share-price threshold.
  • Key HDL risks include clinical-trial and regulatory uncertainty, product quality and supply risks, patient safety, intellectual-property claims, commercialization and market-acceptance risks for the PDS-2 System, payer pricing and reimbursement restrictions, patient-population uncertainty, competition, and the ability to retain qualified personnel.
  • Additional risks include failure to complete the transaction, failure to obtain required approvals or maintain Nasdaq listing, volatility in the combined company’s securities, legal proceedings, disruption to HDL’s operations, and inability to execute post-closing plans.

Most Important Facts for Investors to Verify

  1. Review the definitive merger agreement and confirm the final mix of cash and stock comprising the stated $400 million consideration.
  2. Verify the amount of trust-account cash remaining after shareholder redemptions and whether the $30 million minimum closing-funds condition will be satisfied.
  3. Confirm the status and terms of HDL’s required pre-closing financing.
  4. Monitor the Form S-4, proxy statement/prospectus, shareholder approvals, regulatory clearances, and Nasdaq listing approval.
  5. Assess the potential dilution from up to 11 million earnout shares, financing securities, warrants, and other transaction-related issuances.
  6. Review HDL’s financial statements, clinical and regulatory status, product commercialization, reimbursement assumptions, and risk-factor disclosures when included in subsequent SEC filings.